MX2023008086A - Peptidos resistentes a la plasmina para un indice terapeutico mejorado. - Google Patents
Peptidos resistentes a la plasmina para un indice terapeutico mejorado.Info
- Publication number
- MX2023008086A MX2023008086A MX2023008086A MX2023008086A MX2023008086A MX 2023008086 A MX2023008086 A MX 2023008086A MX 2023008086 A MX2023008086 A MX 2023008086A MX 2023008086 A MX2023008086 A MX 2023008086A MX 2023008086 A MX2023008086 A MX 2023008086A
- Authority
- MX
- Mexico
- Prior art keywords
- amino acids
- plasmin
- administration
- agents
- inclusion
- Prior art date
Links
- 229940012957 plasmin Drugs 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 231100001274 therapeutic index Toxicity 0.000 title 1
- 150000008574 D-amino acids Chemical class 0.000 abstract 3
- 239000013543 active substance Substances 0.000 abstract 2
- 208000017667 Chronic Disease Diseases 0.000 abstract 1
- 102000004674 D-amino-acid oxidase Human genes 0.000 abstract 1
- 108010003989 D-amino-acid oxidase Proteins 0.000 abstract 1
- 150000008575 L-amino acids Chemical class 0.000 abstract 1
- 206010029155 Nephropathy toxic Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000011260 co-administration Methods 0.000 abstract 1
- 230000029087 digestion Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000003527 fibrinolytic agent Substances 0.000 abstract 1
- 238000001802 infusion Methods 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000007918 intramuscular administration Methods 0.000 abstract 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
- 230000007694 nephrotoxicity Effects 0.000 abstract 1
- 231100000417 nephrotoxicity Toxicity 0.000 abstract 1
- 230000000717 retained effect Effects 0.000 abstract 1
- 238000007920 subcutaneous administration Methods 0.000 abstract 1
- 229960000103 thrombolytic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La invención proporciona variantes de un agente activo previamente descrito para el tratamiento de accidentes cerebrovasculares, Tat-NR2B9c, en el que las características de unión al objetivo se retienen mediante la inclusión de L-aminoácidos en el C-terminal y la resistencia la plasmina es conferida por la inclusión de D-aminoácidos. La nefrotoxicidad asociada con los D-aminoácidos puede reducirse incluyendo D-aminoácidos en un número mínimo de posiciones y/o por la coadministración con un inhibidor de D-aminoácido oxidasa. Los agentes activos resultantes tienen varias ventajas, incluyendo la administración al mismo tiempo que agentes trombolíticos sin pérdida significativa de actividad debido a la digestión de plasmina. Los agentes resultantes también son más adecuados para la administración por rutas alternativas a la infusión intravenosa, como la subcutánea, intranasal e intramuscular y para regímenes de dosis múltiples para el tratamiento de condiciones crónicas.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163135498P | 2021-01-08 | 2021-01-08 | |
| US202163147711P | 2021-02-09 | 2021-02-09 | |
| US202163221874P | 2021-07-14 | 2021-07-14 | |
| PCT/US2022/011716 WO2022150655A1 (en) | 2021-01-08 | 2022-01-07 | Plasmin-resistant peptides for improved therapeutic index |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023008086A true MX2023008086A (es) | 2023-08-01 |
Family
ID=82357479
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023008086A MX2023008086A (es) | 2021-01-08 | 2022-01-07 | Peptidos resistentes a la plasmina para un indice terapeutico mejorado. |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4274596A1 (es) |
| JP (1) | JP2024502463A (es) |
| KR (1) | KR20230141958A (es) |
| AU (1) | AU2022206444A1 (es) |
| BR (1) | BR112023013640A2 (es) |
| CA (1) | CA3203688A1 (es) |
| IL (1) | IL304301A (es) |
| MX (1) | MX2023008086A (es) |
| WO (1) | WO2022150655A1 (es) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6998106B1 (en) * | 1998-12-01 | 2006-02-14 | Duke University | Radioconjugation of internalizing antibodies |
| US7510824B2 (en) * | 1999-06-02 | 2009-03-31 | Nono Inc. | Method of screening peptides useful in treating traumatic injury to the brain or spinal cord |
-
2022
- 2022-01-07 BR BR112023013640A patent/BR112023013640A2/pt unknown
- 2022-01-07 CA CA3203688A patent/CA3203688A1/en active Pending
- 2022-01-07 AU AU2022206444A patent/AU2022206444A1/en active Pending
- 2022-01-07 WO PCT/US2022/011716 patent/WO2022150655A1/en active Application Filing
- 2022-01-07 EP EP22737218.2A patent/EP4274596A1/en active Pending
- 2022-01-07 MX MX2023008086A patent/MX2023008086A/es unknown
- 2022-01-07 KR KR1020237026532A patent/KR20230141958A/ko unknown
- 2022-01-07 JP JP2023541501A patent/JP2024502463A/ja active Pending
-
2023
- 2023-07-06 IL IL304301A patent/IL304301A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022150655A1 (en) | 2022-07-14 |
| KR20230141958A (ko) | 2023-10-10 |
| CA3203688A1 (en) | 2022-07-14 |
| IL304301A (en) | 2023-09-01 |
| BR112023013640A2 (pt) | 2023-12-05 |
| AU2022206444A9 (en) | 2024-05-02 |
| EP4274596A1 (en) | 2023-11-15 |
| JP2024502463A (ja) | 2024-01-19 |
| AU2022206444A1 (en) | 2023-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wojtukiewicz et al. | Thrombin—unique coagulation system protein with multifaceted impacts on cancer and metastasis | |
| ES2784136T3 (es) | Combinaciones de lisina de bacteriófagos y antibióticos contra bacterias grampositivas | |
| Kobayashi et al. | Anti-metastatic therapy by urinary trypsin inhibitor in combination with an anti-cancer agent | |
| US8334259B2 (en) | Method of treating endothelial dysfunction comprising administration of a thrombin peptide derivative | |
| NO337485B1 (no) | Anvendelse av en ikke-neurotoksiske plasminogenaktivatorer fra Desmodus rotundus DSPA-alfa-1, for fremstillingen av et terapeutisk medikament for intravenøst anvendelse ved behandling av cerebralt slag | |
| NZ597306A (en) | Mesenchymal stem cell differentiation | |
| RU2013126581A (ru) | Мутанты стрептокиназы и их ковалентно модифицированные формы | |
| WO2007106893A3 (en) | Use of thrombin mutants to inhibit the anticoagulation effect of thrombin inhibitors | |
| Zhang et al. | Effects of ischemic preconditioning on blood–brain barrier permeability and MMP-9 expression of ischemic brain | |
| MX2023008086A (es) | Peptidos resistentes a la plasmina para un indice terapeutico mejorado. | |
| Lyons et al. | Redox dysregulation in the pathogenesis of chronic venous ulceration | |
| WO2008124173A1 (en) | Combination therapy for cardiac revascularization and cardiac repair | |
| WO2022008971A3 (en) | Treatment of severe acute respiratory syndrome-related coronavirus infection with klotho | |
| Kondo et al. | Central and peripheral effects of bradykinin and prostaglandin E2 on blood pressure in conscious rats | |
| US20060029589A1 (en) | Induction of heterozygous FV Leiden carrier status to reduce mortality in sepsis and to prevent organ damage caused by inflammation and/or ischemia-reperfusion injury | |
| Uchima et al. | Identification of a trypsinogen activity stimulating factor produced by pancreatic cancer cells: its role in tumor invasion and metastasis | |
| AU2010200718A1 (en) | Intravenous injection of non-neurotoxic plasminogen activators for the treatment of stroke | |
| Xie et al. | Agkihpin, a novel SVTLE from Gloydius halys Pallas, promotes platelet aggregation in vitro and inhibits thrombus formation in vivo in murine models of thrombosis | |
| US8012935B2 (en) | Synthetic peptides and methods for treating cancer invasion and metastasis | |
| Cavallini et al. | Antiproteasic agents in the prevention of post-ERCP pancreatitis: rationale for use and clinical results | |
| Keck | Site-specific therapeutic effects of protease inhibitors: effect of route of administration in experimental pancreatitis | |
| US20110110920A1 (en) | Method of treating peripheral arterial disease | |
| US20220257714A1 (en) | Use of dermcidin in sterile inflammatory conditions | |
| CA2556805C (en) | Use of factor xiii for stimulating the perfusion of ischemic tissue | |
| MX2022012982A (es) | Agentes inmunoestimulantes en combinación con inhibidores de la angiogénesis. |